Advertisement
JNJ vs MRK
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Merck (MRK) Stock Comparison
Key Takeaways
- JNJ pairs diversified pharmaceuticals and medical technology, while MRK is a concentrated oncology and vaccines play anchored by blockbuster drug Keytruda.
- Relative performance has diverged sharply: MRK has led large-cap pharma with momentum-driven gains, while JNJ has delivered steadier, lower-volatility returns.
- JNJ's pharmaceutical arm is growing strongly, but slowing MedTech growth and talc litigation costs have recently pressured the share price.
- MRK's rally has been driven by pipeline readouts and new-product launches, even as it faces a looming Keytruda patent cliff and a rich valuation.
- JNJ offers a more defensive profile with a dividend yield near 2% and a very low beta (a measure of sensitivity to market moves), whereas MRK carries higher valuation risk and momentum.
- Explore more on these pages: JNJ Major News, JNJ Today's Price Move, MRK Major News, and MRK Today's Price Move.
- For data-driven trading ideas across thousands of tickers, explore Trending AI Robots.
Introduction
Johnson & Johnson (JNJ) and Merck & Co. (MRK) are two of the largest names in U.S. healthcare, yet they represent very different investment profiles. JNJ operates a diversified model spanning innovative medicines and medical technology, while MRK is a more focused pharmaceutical company whose fortunes remain closely tied to oncology and vaccines. This stock comparison is relevant for investors weighing defensive stability against higher-growth momentum, and for traders tracking relative performance and market positioning within the healthcare sector. Understanding the distinct business models, recent momentum, and risk factors of each name can help clarify how these two stocks behave in the current market environment.
JNJ Overview and Recent Performance
Johnson & Johnson is a diversified healthcare conglomerate whose Innovative Medicine segment develops drugs across oncology, immunology, and neuroscience, while its MedTech division sells medical devices and surgical systems. In recent weeks, JNJ reported strong pharmaceutical growth, led by products such as Tremfya, Darzalex, and Carvykti. However, the shares pulled back after the latest quarterly release, as slower MedTech growth and a large litigation charge tied to its proposed talc settlement weighed on sentiment. The company raised its full-year sales and adjusted earnings guidance and has signaled plans to spin off its orthopedics business. With a low beta, a reliable dividend, and a market capitalization among the largest in the sector, JNJ continues to attract investors seeking stability and income over aggressive growth.
MRK Overview and Recent Performance
Merck & Co. is a research-driven pharmaceutical company best known for Keytruda, its flagship oncology drug, which still accounts for roughly half of total revenue. In recent months, MRK has been one of the strongest performers in large-cap pharma, as investors rewarded a series of positive pipeline developments. These include early Phase 3 results from a personalized cancer vaccine program with Moderna and rapid growth from newer products such as Winrevair, Welireg, and Capvaxive. The company also completed acquisitions to deepen its late-stage pipeline. That momentum has moderated somewhat in recent weeks as the stock pulled back from its 52-week high. The key longer-term question is whether its next-generation portfolio can grow quickly enough to offset Keytruda's expected loss of exclusivity, which begins around 2028.
Trending AI Robots
Tickeron maintains a large library of AI Trading Bots that trade thousands of different tickers using varied strategies, timeframes, and risk profiles. Because market conditions change, not every bot is well-suited to the current environment. The Trending AI Robots page curates only the bots that are currently performing best and are most appropriate for today's market. These bots differ in trading style, holding period, underlying ticker set, and performance statistics, giving traders a range of options to explore. Reviewing this section can help you identify automated strategies that align with your own approach to names like JNJ and MRK. Visit the Trending AI Robots page to see which strategies are currently leading.
Head-to-Head Comparison
The clearest contrast between these two stocks is diversification versus concentration. JNJ spreads risk across pharmaceuticals and medical devices, which historically smooths volatility but can dilute growth when one division, such as MedTech, underperforms. MRK concentrates its business in oncology and vaccines, creating higher sensitivity to pipeline outcomes and patent expirations.
Growth drivers also differ. JNJ's recent strength comes from new immunology and oncology drugs offsetting biosimilar erosion of Stelara, while MRK's story hinges on the next generation of drugs replacing Keytruda. On momentum, MRK has outperformed over the past year, but it trades at a premium valuation relative to sales, reflecting high expectations. JNJ trades at a more moderate multiple and offers a dividend yield near 2%, supporting a more defensive market positioning. In terms of risk, JNJ faces litigation and a cooling MedTech segment, while MRK faces concentration risk, elevated valuation, and the approaching patent cliff. Investors must weigh income and stability against momentum and pipeline upside.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor MRK for its stronger recent trend consistency and relative momentum, which are the types of signals momentum-oriented models tend to reward. The stock's sustained outperformance and a sequence of positive clinical catalysts suggest a firmer near-term directional bias than JNJ, which has shown steadier but less dynamic price behavior. That said, JNJ's lower volatility and dividend profile may appeal more to models that prioritize stability and reduced drawdown risk. Any AI-driven preference is probabilistic and based on current trend and positioning data rather than a guaranteed forecast. Traders should treat the comparison as a snapshot of relative positioning that can shift as new earnings, catalysts, and market conditions emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and MRK is a Hold.
JNJ's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for JNJ moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 15 of the 30 cases the stock moved higher. This puts the odds of a move higher at 50%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 37 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 44%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 18 of 47 cases over the following month. The odds of a continued upward trend are 38%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.687) is normal, around the industry mean (-2.729). P/E Ratio (31.047) is within average values for comparable stocks, (20.997). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.040) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
MRK in downward trend: 10-day moving average broke below 50-day moving average on October 13, 2026
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 41 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.
The Moving Average Convergence Divergence Histogram (MACD) for MRK turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 29 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
MRK moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 192 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.292) is normal, around the industry mean (-2.729). MRK's P/E Ratio (111.849) is considerably higher than the industry average of (20.997). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.040) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
JNJ | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | 32 | |
SMR RATING 1..100 | 37 | 79 | |
PRICE GROWTH RATING 1..100 | 43 | 40 | |
P/E GROWTH RATING 1..100 | 7 | 1 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (76) in the Pharmaceuticals Major industry is in the same range as MRK (88). This means that JNJ’s stock grew similarly to MRK’s over the last 12 months.
JNJ's Profit vs Risk Rating (3) in the Pharmaceuticals Major industry is in the same range as MRK (32). This means that JNJ’s stock grew similarly to MRK’s over the last 12 months.
JNJ's SMR Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (79). This means that JNJ’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as JNJ (43). This means that MRK’s stock grew similarly to JNJ’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as JNJ (7). This means that MRK’s stock grew similarly to JNJ’s over the last 12 months.
| JNJ | MRK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 50% | N/A |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 44% | 1 day ago 49% |
| MACD ODDS (%) | 1 day ago 38% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 47% | 1 day ago 49% |
| TrendMonth ODDS (%) | 1 day ago 45% | 1 day ago 43% |
| Advances ODDS (%) | 1 day ago 46% | 8 days ago 57% |
| Declines ODDS (%) | 24 days ago 40% | 3 days ago 51% |
| BollingerBands ODDS (%) | 1 day ago 31% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 39% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 2 FA rating(s) are green while MRK’s FA Score has 2 green FA rating(s).
- JNJ’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 5 TA indicator(s) are bullish while MRK’s TA Score has 3 bullish TA indicator(s).
- JNJ’s TA Score: 5 bullish, 5 bearish.
- MRK’s TA Score: 3 bullish, 5 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +5.14% price change this week, while MRK (@Pharmaceuticals: Major) price change was -5.97% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.41%. For the same industry, the average monthly price growth was -5.87%, and the average quarterly price growth was +2.51%.
Reported Earning Dates
JNJ is expected to report earnings on Jan 26, 2027.
MRK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.41% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement